Abstract
Prenatal mesenchymal stem cell (MSC) transplantation for treatment of osteogenesis imperfecta (OI) has been reported in a human fetus.[1][1] In this issue of Blood , Guillot and colleagues present experimental validation of this approach by demonstrating improvement in the phenotype of the oim mouse
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
